Clik here to view.
Regeneron’s $500M fund spotlights corporate venture’s influential role in...
When Regeneron announced a $500 million corporate venture capital fund last week, it was the first time in years that a storied large pharma had done so. The company said it’s investing $100 million a...
View ArticleWeeks after closing Bristol Myers deal, Karuna's ex-CEO heads to...
How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech. Meury has been appointed CEO at Anthos Therapeutics, just over a month after closing Karuna...
View ArticleClik here to view.
Novartis will change CRO relationships ‘over time’ to align with Biosecure Act
Novartis is “actively” managing its existing relationships with Chinese service providers to mitigate risks if the Biosecure Act passes. CFO Harry Kirsch told media on Tuesday morning that Novartis...
View ArticleAbeona handed a CRL for epidermolysis bullosa cell therapy
Abeona Therapeutics’ shares dropped by almost 50% pre-market Tuesday after receiving an FDA complete response letter for its cell therapy for epidermolysis bullosa. The asset’s PDUFA date is also...
View ArticleSanofi’s BTK inhibitor from Principia deal succeeds in Phase 3 immune...
Sanofi’s $3.7 billion buyout of Principia Biopharma may be starting to pay off after a covalent BTK inhibitor it obtained in the deal hit the primary endpoint in a Phase 3 test in patients with an...
View ArticleIn biggest-ever bet on using AI to design drugs, biotech heavyweights launch...
A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug R&D using artificial intelligence, the...
View ArticleClik here to view.
Headspace will add more mental-health services to its consumer business,...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Headspace, best known for its app that guides people through meditation, now wants to help more of its...
View ArticleClik here to view.
AI drug discovery startup BenevolentAI cuts 30% of staff, closes US office
BenevolentAI is making its second round of layoffs in a year, as the company continues to refine the business strategy around its AI drug discovery platform. Having completed a market assessment,...
View ArticleClik here to view.
FDA approves ImmunityBio's bladder cancer therapy Anktiva
ImmunityBio scored an FDA approval for its once-rejected drug combo for bladder cancer, the biotech announced Monday, sending its stock up nearly 25% in premarket trading. The agency approved the drug...
View ArticleARCH’s Bob Nelsen on launching Xaira with $1B+ to reinvent drug discovery...
In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ideas that carry huge amounts of risk and reward. His latest — on AI startup...
View ArticleClik here to view.
Incyte inks $750M deal for immune and neuro biotech Escient
Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug candidates. The deal gives the Delaware-based drugmaker access to once-daily...
View ArticleClik here to view.
Inside Vertex, Alpine's negotiations leading to $4.9B M&A deal
Jeffrey Leiden wanted Alpine. The Vertex chair, who had led early development of the world’s top-selling medicine while at Abbott in the 2000s, had his eyes on Alpine Immune Sciences’ investigational...
View ArticleLilly nabs injectable medicines facility from Nexus Pharma
To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year. Lilly will...
View ArticleMarc Tessier-Lavigne on leaving Stanford and joining AI mega-startup Xaira
Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup launches: Xaira Therapeutics, which has secured over $1...
View ArticleClik here to view.
Pascal Soriot’s been pushing for US-sized CEO pay for more than a decade. Now...
Bioregnum Opinion Column by John Carroll Back in 2013, Pascal Soriot’s first full year at the helm of a tottering AstraZeneca, he landed a pay package worth about $5.5 million. By pharma CEO standards,...
View ArticleClik here to view.
Neurocrine’s depression drug passes Phase 2 trial
Neurocrine Biosciences reported that its pill for major depressive disorder reduced scores on a depression severity scale at about one month in a Phase 2 trial. In the SAVITRI study, 183 adult...
View ArticleClik here to view.
Pharma companies tone down ESG mentions, but not ambitions
Pharma companies are scaling back the use of terms like “ESG” and “diversity, equity and inclusion,” much like companies in other industries. In pharma 10-K filings, mentions of ESG, sustainability, or...
View ArticleBrise raises $20M; Taro shareholder criticizes Sun Pharma deal
Plus, news about Tarsus Pharmaceuticals and Biohaven: Brise Pharmaceuticals raises $20M: The funding comes from Shunxi Fund, Sherpa Healthcare Partners and Qiming Ventures, among other investors. The...
View ArticleClik here to view.
Novartis’ simplified strategy takes shape as the company seeks former Bristol...
Novartis appears headed in the right direction now that Sandoz has been spun out, operations have been streamlined and the Swiss company is reporting higher-than-expected sales for several medicines....
View ArticleMarketingRx roundup: Cannes ad festival speakers to include Pfizer, Novo...
Pharma companies set for Cannes ad creativity festival: Pfizer and Novo Nordisk are both set to take the main stages at Cannes’ advertising confab this summer. The just-announced program highlights...
View Article